The trademark application REVERSE IMMUNIZATION was filed by CANOPY IMMUNO-THERAPEUTICS LTD, a corporation established under the laws of the State of Israel (the "Applicant"). Application refused.
The application was filed in English (German was selected as the second language).
Change of name and professional address of the trademark registration was recorded on January 26, 2023.
The Appeal with reference B R0634/2022-4 was Application rejected according to Article 33(2) EUTMR with decision issued on September 15, 2022 by the EUIPO. The Refusal with reference B 018510903 was Rejected according to Article 7(1)(b) EUTMR with decision issued on February 15, 2022 by the EUIPO. The Refusal with reference B 018510903 was Rejected according to Article 7(1)(b) EUTMR with decision issued on May 18, 2023 by the EUIPO.
Goods And Services
The mark was filed in class 5 with following description of goods:
Biologics, biosimilars and protein preparations excluding an antibody for the treatment of autoimmune, allergic and in inflammatory diseases and disorders
Biologics, biosimilars and protein preparations excluding an antibody for the treatment of autoimmune, allergic and inflammatory diseases by eliminating specific lymphocytes lineages or modulating the immune response using a variety of organic compounds and recombinant proteins
Biologics, biosimilars and protein preparations excluding an antibody that modulate the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the antibody creation and antigen specific immune response in autoimmune, allergic and inflammatory diseases
Biologics, biosimilars and protein preparations excluding an antibody that modulate the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the creation of the antibodies IgG, IgE or IgA and antigen specific immune response in autoimmune, allergic and inflammatory diseases
Biologics, biosimilars and protein preparations excluding an antibody with potential immunomodulation activity to treat under and over responsiveness of the immune system.